DiaMedica Therapeutics (DMAC) FCF Margin (2018)

DiaMedica Therapeutics (DMAC) posted quarterly FCF Margin of 371.8% for Q3 2018.

DiaMedica Therapeutics (DMAC) FCF Margin (2018) Analysis & Trends

DiaMedica Therapeutics' FCF Margin history runs 1 years deep, the most recent figure standing at 371.8% for Q3 2018.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Margin (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 30.39%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 13.35%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 25.68%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -77,594.17%
7 Royalty Pharma 33.72 Bn 35.84 Bn - 70.82%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 22.62%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -22.35%
10 DiaMedica Therapeutics 360.22 Mn 360.22 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2018 -371.80%